M
Marc Chevrier
Researcher at Janssen Pharmaceutica
Publications - 28
Citations - 1683
Marc Chevrier is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Ustekinumab & Infliximab. The author has an hindex of 13, co-authored 28 publications receiving 1358 citations.
Papers
More filters
Journal ArticleDOI
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Robert E. Kalb,David Fiorentino,Mark Lebwohl,John Toole,Yves Poulin,Arnon D. Cohen,Kavitha Goyal,Steven Fakharzadeh,S. Calabro,Marc Chevrier,Wayne Langholff,Yin You,Craig L. Leonardi +12 more
TL;DR: Results from PSOLAR suggest a higher risk of serious infections with adalimumab and infliximab compared with nonmethotrexate and nonbiologic therapies.
Journal Article
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kim A. Papp,Alice B. Gottlieb,Luigi Naldi,David M. Pariser,Ho,Goyal K,Fakharzadeh S,Marc Chevrier,Calabro S,Wayne Langholff,Gerald G. Krueger +10 more
TL;DR: Analysis of 2014 PSOLAR data identified no increased risk of malignancy, MACE, serious infection, or mortality with ustekinumab.
Journal ArticleDOI
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
Miguel Regueiro,Brian G. Feagan,Bin Zou,Jewel Johanns,Marion Blank,Marc Chevrier,S Plevy,John W. Popp,Freddy Cornillie,Milan Lukas,Silvio Danese,Paolo Gionchetti,Stephen B. Hanauer,Walter Reinisch,Walter Reinisch,William J. Sandborn,Dario Sorrentino,Dario Sorrentino,Paul Rutgeerts,H. Debinski,Timothy H. Florin,D. J. Hetzel,I. Lawrance,G. Radford-Smith,A. Sloss,D. Sorrentino,S. Gassner,T. Haas,G. Reicht,W. Reinisch,W. Reinisch,M. Strasser,Harald Vogelsang,Peter Bossuyt,O. Dewit,G. D'Haens,Denis Franchimont,Edouard Louis,Severine Vermeire,Charles N. Bernstein,Raymond Bourdages,N. Chiba,S. S. Dhalla,Brian G. Feagan,Richard N. Fedorak,J. R. Lachance,Remo Panaccione,M. Ropeleski,B. Singh Salh,Martin Lukas,J.-F. Colombel,Matthieu Allez,Pierre Desreumaux,J.L. Dupas,Jean-Charles Grimaud,Xavier Hébuterne,D. Laharie,Eric Lerebours,Laurent Peyrin-Biroulet,Jean-Marie Reimund,Stephanie Viennot,Frank Zerbib,C. Antoni,Raja Atreya,Daniel C. Baumgart,C. Berg,U. Boecker,G. Bramkamp,C. Bünning,Robert Ehehalt,Stefanie Howaldt,Torsten Kucharzik,H. G. Lamprecht,J. Mudter,J. C. Preiss,S. Schreiber,Ursula Seidler,István Altorjay,János Banai,Peter L. Lakatos,Márta Varga,Áron Vincze,Irit Avni-Biron,S. Fishman,Gerald Fraser,Eran Goldin,Daniel Rachmilewitz,V. F. Annese,Sandro Ardizzone,Livia Biancone,Fabrizio Bossa,Silvio Danese,Walter Fries,P. Gionchetti,Giovanni Maconi,Giovanni Terrosu,Paolo Usai,G R D’Haens,Richard B. Gearry,J. Hill,David Rowbotham,Michael Schultz,R. S. Stubbs,D. Wallace,Russell S. Walmsley,John Wyeth,Ewa Małecka-Panas,L. Paradowski,Jaroslaw Regula,I. P. Beales,Simon Campbell,A. B. Hawthorne,M Parkes,Simon Travis,Jean-Paul Achkar,B. W. Behm,Stephen J. Bickston,K. J. Brown,Michael Chiorean,W. J S Devilliers,D. E. Elliott,D. Grunkmeier,J. W. Hamilton,S. B. Hanauer,J. S. Hanson,R. Hardi,D. J. Helper,Hans H Herfarth,Peter D.R. Higgins,W. H. Holderman,R. Kottoor,M. D. Kreines,B. I. Leman,X. Li,Edward V. Loftus,M. Noar,I. Oikonomou,Jane E. Onken,K. A. Peterson,R. P. Phillips,Charles Randall,M. Ricci,T. Ritter,David T. Rubin,Michael Safdi,W J Sandborn,L. Sauberman,Ellen Scherl,R. P. Schwarz,S. Sedghi,Ira Shafran,Charles A. Sninsky,I. Stein,Jason M. Swoger,J. Vecchio,D. I. Weinberg,L. D. Wruble,V. Yajnik,Ziad Younes +158 more
TL;DR: Infliximab is not superior to placebo in preventing clinical recurrence after CD-related resection, however, infliximab does reduce endoscopic recurrence.
Journal ArticleDOI
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
Ronald F van Vollenhoven,Ronald F van Vollenhoven,Bevra H. Hahn,George C. Tsokos,Carrie Wagner,Peter Lipsky,Zahi Touma,Victoria P. Werth,Victoria P. Werth,R. Gordon,B. Zhou,Benjamin Hsu,Marc Chevrier,Manon Triebel,Jarrat Jordan,Shawn Rose +15 more
TL;DR: The addition of ustekinumab to standard-of-care treatment resulted in better efficacy in clinical and laboratory parameters than placebo in the treatment of active systemic lupus erythematosus and had a safety profile consistent with usteksineumab therapy in other diseases.
Journal ArticleDOI
Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group.
Mathurin Fumery,Philippe Seksik,Philippe Seksik,Claire Auzolle,Nicolas Munoz-Bongrand,Jean-Marc Gornet,Gilles Boschetti,Eddy Cotte,Anthony Buisson,Anne Dubois,Benjamin Pariente,Philippe Zerbib,Najim Chafai,Carmen Stefanescu,Yves Panis,Philippe Marteau,Karine Pautrat,Charles Sabbagh,Jérôme Filippi,Marc Chevrier,Pascal Houzé,Xavier Jouven,Xavier Treton,Matthieu Allez +23 more
TL;DR: In this large, nationwide, prospective cohort of Crohn’s disease patients, postoperative complications were observed after 21% of the ileocecal resections, and corticosteroid treatment in the 4 weeks before surgery was significantly associated with an elevated postoperative complication rate.